Saad Z. Usmani, MD
Although physicians cannot predict exactly when a patient with multiple myeloma will go into relapse, certain high-risk features can alert providers to those at the highest risk for early relapse. Once a patient relapses, physicians can use a patient’s prior exposure to therapy and type of relapse to guide the next line of treatment, said Saad Z. Usmani, MD.
, Usmani, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, shared insight on approaches to early relapse in myeloma given the evolution of frontline treatment advances.
OncLive: How has first-line newly diagnosed multiple myeloma treatment evolved?
: The landscape of myeloma has evolved over the last 10 years. We've gone from treating patients with one drug and one mechanism of action, to doublets with 2 or 3 different mechanisms of action, to 3-drug regimens. This is based on data from the SWOG S0777 trial, FIRST trial, and most recently, the MAIA and ALCYONE studies for transplant-ineligible patients.
... to read the full story